Donald A Bergstrom Relay Therapeutics, Inc. (RLAY) insider trading activity

Donald A Bergstrom is President, R&D of Relay Therapeutics, Inc.. Currently has a direct ownership of 524,081 shares of RLAY, which is worth approximately $3.27 Million. The most recent transaction as insider was on Jul 29, 2024, when has been sold 2,698 shares (Common Stock) at a price of $8.85 per share, resulting in proceeds of $23,877. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 524K

0.63% 3M change

120.29% 12M change

Total Value Held $3.27 Million

Donald A Bergstrom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 29 2024	SELL Open market or private sale	$23,877 $8.85 p/Share	2,698 Reduced 0.51%	524,081 Common Stock
Jun 27 2024	SELL Open market or private sale	$4,056 $6.26 p/Share	648 Reduced 0.12%	526,779 Common Stock
Apr 29 2024	SELL Open market or private sale	$17,136 $6.38 p/Share	2,686 Reduced 0.51%	527,427 Common Stock
Mar 27 2024	SELL Open market or private sale	$5,890 $7.7 p/Share	765 Reduced 0.14%	530,113 Common Stock
Jan 29 2024	SELL Open market or private sale	$30,635 $9.64 p/Share	3,178 Reduced 0.6%	530,878 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	300,000 Added 35.97%	534,056 Common Stock
Dec 27 2023	SELL Open market or private sale	$11,245 $11.51 p/Share	977 Reduced 0.42%	234,056 Common Stock
Oct 30 2023	SELL Open market or private sale	$20,809 $6.03 p/Share	3,451 Reduced 1.45%	235,033 Common Stock
Sep 27 2023	SELL Open market or private sale	$5,430 $8.38 p/Share	648 Reduced 0.27%	238,484 Common Stock
Jul 28 2023	SELL Open market or private sale	$31,659 $11.8 p/Share	2,683 Reduced 1.12%	237,904 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$13,115 $10.68 p/Share	1,228 Added 0.51%	241,815 Common Stock
Jun 27 2023	SELL Open market or private sale	$7,841 $12.12 p/Share	647 Reduced 0.27%	240,587 Common Stock
Apr 28 2023	SELL Open market or private sale	$15,434 $11.16 p/Share	1,383 Reduced 0.57%	242,701 Common Stock
Mar 27 2023	SELL Open market or private sale	$11,719 $15.36 p/Share	763 Reduced 0.31%	244,084 Common Stock
Jan 30 2023	SELL Open market or private sale	$30,809 $21.56 p/Share	1,429 Reduced 0.58%	244,847 Common Stock
Jan 17 2023	BUY Grant, award, or other acquisition	-	160,390 Added 39.44%	246,276 Common Stock
Dec 27 2022	SELL Open market or private sale	$14,200 $14.49 p/Share	980 Reduced 1.13%	85,886 Common Stock
Nov 01 2022	SELL Open market or private sale	$182,000 $22.75 p/Share	8,000 Reduced 8.43%	86,866 Common Stock
Nov 01 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 7.78%	94,866 Common Stock
Oct 28 2022	SELL Open market or private sale	$39,138 $21.54 p/Share	1,817 Reduced 2.05%	86,866 Common Stock
Oct 03 2022	SELL Open market or private sale	$179,440 $22.43 p/Share	8,000 Reduced 8.27%	88,683 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 7.64%	96,683 Common Stock
Sep 27 2022	SELL Open market or private sale	$22,184 $22.73 p/Share	976 Reduced 1.09%	88,683 Common Stock
Sep 08 2022	SELL Open market or private sale	$750,000 $30.0 p/Share	25,000 Reduced 21.8%	89,659 Common Stock
Sep 08 2022	BUY Exercise of conversion of derivative security	$103,000 $4.12 p/Share	25,000 Added 17.9%	114,659 Common Stock

Also insider at

FUSN

Fusion Pharmaceuticals Inc. Healthcare

DAB